Benevolent AI BAIVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.72
- Day Range
- $0.71–0.71
- 52-Week Range
- $0.56–0.72
- Bid/Ask
- — / —
- Market Cap
- $87.98 Mil
- Volume/Avg
- 415 / 46,226
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.18
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 248
- Website
- https://www.benevolent.com
Comparables
Valuation
|
Metric
|
BAIVF
|
RPTX
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.68 | 2.62 |
Price/Sales | 9.18 | 2.80 | 30.74 |
Price/Cash Flow | — | — | — |
Price/Earnings
BAIVF
RPTX
NYKD
Financial Strength
|
Metric
|
BAIVF
|
RPTX
|
NYKD
|
|---|---|---|---|
Quick Ratio | 2.08 | 6.11 | 7.91 |
Current Ratio | 3.65 | 6.24 | 8.04 |
Interest Coverage | −233.69 | — | −235.75 |
Quick Ratio
BAIVF
RPTX
NYKD
Profitability
|
Metric
|
BAIVF
|
RPTX
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −38.46% | −23.00% | −19.18% |
Return on Equity (Normalized) | — | −29.04% | −26.31% |
Return on Invested Capital (Normalized) | −47.53% | −33.39% | −30.96% |
Return on Assets
BAIVF
RPTX
NYKD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hqypjzyj | Vmczv | $547.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jdrcfxrw | Ndvsjl | $105.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kbjxrpdjn | Mjtxbm | $104.0 Bil | |
MRNA
| Moderna Inc | Gxpggqfg | Dhyf | $46.8 Bil | |
ARGX
| argenx SE ADR | Vwwchkcdc | Thhsp | $23.2 Bil | |
BNTX
| BioNTech SE ADR | Fywvqvsp | Zjhp | $22.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gjmvvzd | Jdcpdg | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ffvhfdzcj | Mkxvzs | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pnqzfrxrt | Ftkzyh | $12.8 Bil | |
INCY
| Incyte Corp | Lcyzmlwml | Ftqhh | $12.1 Bil |